Action(s) initiated or orders passed

Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Date: 10 September 2026 Corporate relationship Department, National Stock Exchange of India, Limited BSE Limited, Exchange Plaza, 5th Floor, 1st Floor, Rotunda Building Plot No. C/1, G Block, Bandra-Kurla Complex, P.J Towers Dalal Street, Fort, Bandra (E), Mumbai 400001 Mumbai 400051 Stock Code: BSE – 530549 / NSE – SHILPAMED Dear Sir/Ma’am, Sub: Initiation of NCLT Order on FTF Pharma Private Limited, a Wholly Owned Subsidiary of Shilpa Medicare Limited. Ref: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’). Pursuant to Regulation 30 of Listing Regulations , we hereby inform that the Hon’ble National Company Law Tribunal, Ahmedabad Bench – Court II, vide its order pronounced on 9 September 2026 in CP (IB) No. 346 (AHM) 2025, has admitted the application filed under Section 9 of the Insolvency and Bankruptcy Code, 2016 (“IBC”) by Immacule Lifesciences Private Limited against FTF Pharma Private Limited (“FTF Pharma”), a Wholly Owned Subsidiary of Shilpa Medicare Limited (“the Company”), and has ordered commencement of the Corporate Insolvency Resolution Process (“CIRP”) against FTF Pharma. The Company is in discussions with its legal advisors to evaluate the overall legal position and the future course of action for the same. We will provide requisite updates at appropriate time on any further development on the matter. A copy of the order of the Hon’ble NCLT dated 9 September 2026 is enclosed herewith for information and records. The requisite details as prescribed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated 30th January 2026, are enclosed herewith as Annexure A. This is for your information and records. For SHILPA MEDICARE LIMITED Ritu Tiwary Company Secretary & Compliance Officer Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Master Circular No. HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated 30th January 2026. Annexure A Name of the authority Hon’ble National Company Law Tribunal, Ahmedabad Bench – Court II Nature and details of the action(s) taken or order(s) The Hon’ble NCLT, Ahmedabad Bench – Court II, passed vide order dated September 9, 2026, has admitted CP (IB) No. 346 (AHM) 2025 filed by Immacule Lifesciences Private Limited under Section 9 of the Insolvency and Bankruptcy Code, 2016 (“IBC”) against FTF Pharma Private Limited and ordered initiation of Corporate Insolvency Resolution Process (CIRP) against FTF Pharma Private Limited. The Hon’ble NCLT has also ordered commencement of moratorium under Section 14 of the IBC and appointed Mr. Sunil Kumar Kedia, IBBI Registration No. IBBI/IPA-001/IP-P00028/2016- 2017/10064, as the Interim Resolution Professional (IRP). The CIRP shall commence with effect from the date of the order. Date of receipt of direction or order, including any September 9, 2026, being the date of pronouncement ad-interim or interim orders, or any other of the order. communication from the authority Details of the violation(s)/contravention(s) The proceedings were initiated under Section 9 of the committed or alleged to be committed IBC in respect of an alleged operational debt of ₹2,18,03,319/- claimed by Immacule Lifesciences Private Limited against FTF Pharma Private Limited. The Hon’ble NCLT held that the outstanding debt was proved and that there was no valid pre-existing dispute sufficient to reject the application. No violation or contravention by the listed entity has been alleged or determined in the said order. Impact on financial, operation or other activities of The order relates to initiation of CIRP against FTF the listed entity, quantifiable in monetary terms to Pharma Private Limited, a subsidiary of the the extent possible. Company. The initiation of CIRP and consequential moratorium may have an impact on the financial and Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 operational activities of the subsidiary. The impact, if any, on the financial, operational or other activities of the listed entity is presently not ascertainable /quantifiable. The Company will continue to monitor the CIRP proceedings and make further disclosures as may be required under applicable laws. The Company is in discussions with its legal advisors to evaluate the overall legal position and the future course of action for the same. We will provide requisite updates at appropriate time on any further development on the matter.